Beta Capital has successfully sold its stake in Matera, a technology firm specializing in sustainable nanoparticle-based solutions for combatting viruses and bacteria, amidst rising demand for public health innovations.

Target Information

Matera has pioneered a proprietary technology that combines biocidal agents with nanoparticles to form advanced nanoconjugates. These nanoconjugates are characterized by their enhanced stability and unique properties, which position them as a superior solution in combating viruses and bacteria in public spaces. Matera's approach ensures sustainability by utilizing a smaller amount of the active agent without releasing it into the environment, making it an eco-friendly alternative.

In light of increasing market demand for effective solutions to public health challenges, Matera is set to expand its operations supported by an international framework. With years of extensive research and development, the company is on a trajectory for significant growth, contributing valuable innovations to various industries.

Industry Overview in Portugal

The technology sector in Portugal, particularly in healthcare and public health applications, has been gaining traction. Over the last decade, the country has invested heavily in research and innovation, resulting in